Smyth C J, Bartholomew B A, Mills D M, Steigerwald J C, Strong S J, Recart S
Arch Intern Med. 1975 Jun;135(6):789-93.
Cyclophosphamide in high doses was given for six months to 19 patients with rheumatoid arthritis. A second group of patients with rheumatoid arthritis whose conditions were stable on low-dose prednisone received in addition either cyclophosphamide or placebo for six months. Measurements of joint function and joint inflammation were used to estimate disease activity. Joint inflammation progressively decreased and joint function improved in the high-dose group. The low-dose cyclophosphamide-plus-prednisone group had a similar response that was different from the prednisone-plus-placebo group. Cyclophosphamide toxicity was common in the high-dose group and minimal in the low-dose-plus-prednisone group. Cyclophosphamide therapy improved the arthritis of these patients. The results were almost as good in the low-dose-plus-prednisone group, and the toxicity was much less.
对19例类风湿性关节炎患者给予高剂量环磷酰胺治疗六个月。第二组类风湿性关节炎患者在低剂量泼尼松治疗下病情稳定，另外给予环磷酰胺或安慰剂治疗六个月。通过测量关节功能和关节炎症来评估疾病活动度。高剂量组中关节炎症逐渐减轻，关节功能得到改善。低剂量环磷酰胺加泼尼松组有类似反应，与泼尼松加安慰剂组不同。高剂量组中环磷酰胺毒性常见，而低剂量加泼尼松组中毒性最小。环磷酰胺治疗改善了这些患者的关节炎。低剂量加泼尼松组的结果几乎同样良好，且毒性小得多。
